Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Unknown 2Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Carcinoma, Hepatocellular 11Stomach Neoplasms 10Esophageal Squamous Cell Carcinoma 10Squamous Cell Carcinoma of Head and Neck 9Lung Neoplasms 8Colorectal Neoplasms 8Rectal Neoplasms 5Advanced Solid Tumor 5Head and Neck Neoplasms 4Triple Negative Breast Neoplasms 3Esophageal Neoplasms 3Cholangiocarcinoma 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Neoplasm, Residual 2Nasopharyngeal Carcinoma 2Lymphoma 2Leukemia, Myeloid, Acute 2Colonic Neoplasms 2Biliary Tract Neoplasms 2Advanced Solid Tumour 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of External Auditory Canal 1Solid Tumor, Adult 1Solid Tumor 1Small Cell Lung Cancer Extensive Stage 1Simpson-Golabi-Behmel syndrome 1Sarcoma 1Renal Pelvic Carcinoma 1

Interventions

Cyclophosphamide 23venetoclax 17Dexamethasone 16pembrolizumab 15fludarabine 15Cytarabine 13pomalidomide 8Rituximab 8Gemcitabine 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7selinexor 6Paclitaxel 6Injections 6Immunotherapy, Adoptive 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Oxaliplatin 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Recurrence × tislelizumab × Clear all
NCT06420440 2025-05-01

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

Tongji Hospital

Phase 2 Recruiting
160 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡